Aller au contenu

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.

Nom du journal : Eur Urol

Année : 2024

Volume : 85

Page de départ : 274-282

Auteurs: Colomba, E, Jonas, SF, Eymard, JC, Delva, R, Brachet, PE, Neuzillet, Y & al,